Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

CellaVision

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
27.7.
2022

On July 27, 2022, CellaVision® announces the launch of DIFF-Line ™ by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago.

DIFF-Line ™ by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox.

Muut analyysit
20.7.
2022

Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year. We increase our Base case to SEK 370 (340) and fair value range to SEK 230 – 520 (220 – 490) per share.

Tiedotteet
20.7.
2022

April 1-June 30, 2022

Tiedotteet
6.7.
2022

CellaVision AB (publ) will publish the Interim report for the second quarter, on July 20, 2022 at 7:20 CEST. The report will be available at ir.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where
Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
20.5.
2022

CellaVision invites institutional investors, financial analysts and media to join its Capital Markets Day on June 16, 2022.

During the event, CellaVision’s executive management will present the next exciting phase of our strategic vision: The Power of Focus – Enhancing the Future of Microscopy.

Join us for an update on our operational priorities and focused insights on new growth opportunities over the next five years.

Tiedotteet
11.5.
2022

The following resolutions were passed at the Annual General Meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 11 May 2022 in Lund.

Muut analyysit
10.5.
2022

Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.

Tiedotteet
10.5.
2022

Organic sales growth:
Q1, 2022: 15% (7)

EBITDA margin:
Q1, 2022: 36% (34)

1 January-31 March 2022

Tiedotteet
26.4.
2022

CellaVision AB (publ) will publish the Interim report for the first quarter, on May 10, 2022 at 7:20 CEST. The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
25.4.
2022

CellaVision will host a Capital Markets Day on June 16, 2022. During the day, executive management will present the company’s updated strategic direction, which aims to develop and broaden the company’s operations over the next five years. The event is planned to be held at CellaVision head quarter in Lund. Invitation will be sent out closer to the event.

CellaVision